ACCESS SOLUTIONS

Expanded Access Programs

Tanner offers a full range of services to support the design, implementation and execution of Expanded Access Programs in the US.

HOW IT WORKS

Expanding hope

Expanded Access Programs (EAPs) are a pathway created and regulated by the US FDA that allows biopharmaceutical companies to provide investigational new drugs (INDs) to patients with serious diseases or conditions who have exhausted approved therapy and cannot participate in a clinical trial. The FDA has defined specific criteria that determine which part of its program is most appropriate for the medicine in development.

Whether a medication is requested ad hoc for single patients or for a group of patients, Tanner offers a full range of services to support the design, implementation and execution of Expanded Access Programs in the US.

Contact Us

Individual Patient

Intermediate Size

Treatment IND

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.